- The FDA has granted Breakthrough Device Designation to Abbott Laboratories (NYSE:ABT) deep brain stimulation (DBS) system in treatment-resistant depression (TRD), a form of major depressive disorder (MDD).
- Abbott’s DBS system is a personalized, adjustable therapy that involves implanting thin wires (or leads) – into targeted areas of the brain.
- A pulse generator implanted under the skin in the chest is connected to the leads and produces electrical impulses that can modulate abnormal brain activity.
- While Abbott’s DBS system has traditionally been used to help control symptoms in movement disorders, such as Parkinson’s disease and essential tremor, evidence suggests that implanting electrodes in the part of the brain that regulates mood could help reduce symptoms of TRD.
- Abbott is working with the FDA to develop a plan to evaluate the device’s safety and effectiveness.
- Each year, 2.8 million Americans will fail multiple depression therapies and be diagnosed with treatment-resistant depression.
- Price Action: ABT shares are up 0.60% at $109.54 during the market session on the last check Tuesday.
Apple’s Challenges Go Beyond Latest Economic Concerns; Why This Analyst Feels Cupertino Can Bounce Fairly Quickly
Apple, Inc. (NASDAQ: AAPL) rumored curb on spending and hiring across teams in 2023 is in anticipation of an economic slump – the first time the company is looking vulnerable to external factors such as rising interest rate, stronger U.S.
